Moreover, by multidisciplinary approach, we clarify the inner mechanism; explore the potential of Trp restriction dietary or pharmacologic inhibition of related molecules in sensitizing bladder cancer to chemo-drugs or STING agonist; and verify the clinical relevance with related genes, metabolic pathways, or metabolites. The gene discussed is STING1; the disease is urinary bladder carcinoma.